NEW YORK, July 11, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic, off-the-shelf invariant natural killer T (iNKT) ...
agenT-797 demonstrates pathogen suppression, lung immune restoration and tissue repair activation, supporting Ongoing Phase 2 trial Sequential immunotherapy with agenT-797 and N-803, an FDA-approved ...
Antigen-presenting cells activate invariant natural killer T (iNKT) cells, and this combination with α-galactosylceramide subsequently activates the body’s own T cells to fight tumors. This image was ...
Hosted on MSN
Biotech breakthrough? INKT stock skyrockets 530% after cell therapy cures testicular cancer
MiNK Therapeutics (NASDAQ: INKT) saw its stock price soar by over 530% today—hitting a peak of $65.55—after the company revealed a potential breakthrough in cancer treatment. MiNK announced that one ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results